Summary
Tozinameran has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). No registered clinical trial in this database tests Tozinameran specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 1 meta-analysis and 2 clinical trial publications. Publication years run from 2022 to 2023. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Post-Acute COVID/Vaccination Syndrome ranks 675 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 28.0 (trials 0.0, literature 8.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (2 clinical trial publications, 1 meta-analysis) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Tozinameran to Long COVID / Post-Acute COVID Sequelae (PACVS) in the current OSMF trial extract.
Published literature
- Clinical trial publication Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesShaw RH, Greenland M, Stuart ASV et al. · The Journal of infection · 2023 · PMID 37028454
- Meta-analysis Vaccines and Bell's palsy: A narrative reviewBertin B, Grenet G, Pizzoglio-Billaudaz V et al. · Therapie · 2023 · PMID 36038397
- Clinical trial publication Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialShaw RH, Liu X, Stuart ASV et al. · The Lancet. Respiratory medicine · 2022 · PMID 35690076
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Tozinameran approved for Long COVID / Post-Acute COVID Sequelae (PACVS)?
Tozinameran has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Tozinameran in clinical trials for Long COVID / Post-Acute COVID Sequelae (PACVS)?
No registered clinical trial in this database tests Tozinameran specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Tozinameran in Long COVID / Post-Acute COVID Sequelae (PACVS)?
Synthesis-level literature links Tozinameran to Long COVID / Post-Acute COVID Sequelae (PACVS), but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.